3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
36
Phase 1
22
Phase 3
19
Phase 1/2
14
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Thymoma
1
Thymic epithelial tumor
1
Squamous NSCLC
1
Mediastinal Neoplasms
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
1
Interventions
Pemetrexed
13
Carboplatin
13
Docetaxel
11
Cisplatin
11
pembrolizumab
9
Paclitaxel
8
Gemcitabine
7
Erlotinib Hydrochloride
4
Bevacizumab
4
anlotinib
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Gefitinib
3
Dexamethasone
3
dexamethasone acetate
2
dexamethasone 21-phosphate
2
cobimetinib
2
cemiplimab
2
auricularum
2
atezolizumab
2
apatinib
2
Vemurafenib
2
Surgical Procedures, Operative
2
Standard of Care
2
Specimen Handling
2
Ramucirumab
2
Calcium Dobesilate
2
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Non-Small-Cell Lung
×
130-nm albumin-bound paclitaxel
×
Clear all
NCT07365319
2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3
Recruiting
750 enrolled